Raymond James Financial Services Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,008	Closed	-$68K	–	2796
2017 Q4	$68K	Buy	13,008 +470	+4%	+$2.88K	﹤0.01%	2416
2017 Q3	$77K	Hold	12,538	–	–	﹤0.01%	2420
2017 Q2	$91K	Hold	12,538	–	–	﹤0.01%	2355
2017 Q1	$66K	Sell	12,538 -218	-2%	-$1.47K	﹤0.01%	2297
2016 Q4	$92K	Hold	12,756	–	–	﹤0.01%	2201
2016 Q3	$119K	Buy	12,756 +1,941	+18%	+$16.1K	﹤0.01%	2130
2016 Q2	$68K	Buy	+10,815	New	+$69.6K	﹤0.01%	2144

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Raymond James Financial Services Advisors's PETX Position: Q1 2018 in Review

Raymond James Financial Services Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2018, closing a stake of 13,008 shares — an estimated $68K sold.

Raymond James Financial Services Advisors first reported a position in PETX in Q2 2016 and held it in 7 quarters. The position peaked at $119K in Q3 2016. 103 funds tracked by Wall St. Rank hold PETX as of Q1 2018.

Raymond James Financial Services Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Raymond James Financial Services Advisors sold 13,008 Aratana Therapeutics, Inc. shares in Q1 2018, an estimated $68K.
Raymond James Financial Services Advisors first reported a position in Aratana Therapeutics, Inc. in Q2 2016 and held it in 7 quarters.
Raymond James Financial Services Advisors's Aratana Therapeutics, Inc. position peaked at $119K in Q3 2016.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2018.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2018, filed 16 Apr 2018.